Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295940 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3841136 in Healthy and Overweight Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT05295940 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 148 participants.
The verdict
NCT05295940, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.
Interventions
- DRUG Placebo
- DRUG LY3841136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05295940
The ClinicalTrials.gov registry entry for NCT05295940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05295940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05295940 about?
NCT05295940 is a clinical study titled "A Study of LY3841136 in Healthy and Overweight Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to...
What is the current status of trial NCT05295940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2022-03-30. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT05295940?
The interventions under investigation include: Placebo (DRUG), LY3841136 (DRUG).
Who is sponsoring clinical trial NCT05295940?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.